Log In
Print this Print this

Livatag, doxorubicin (Livatag doxorubicin Transdrug) (BA-003)

  Manage Alerts
Collapse Summary General Information
Company Onxeo S.A.
DescriptionNanoparticle formulation of doxorubicin
Molecular Target DNA
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationLiver cancer
Indication DetailsTreat advanced hepatocellular carcinoma (HCC); Treat hepatocellular carcinoma (HCC)
Regulatory Designation

U.S. - Fast Track (Treat hepatocellular carcinoma (HCC));
U.S. - Orphan Drug (Treat hepatocellular carcinoma (HCC));
EU - Orphan Drug (Treat hepatocellular carcinoma (HCC))


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today